Mounjaro self-injection tutorials: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtags, @nathalievankralingen is walking her 252K followers through how she self-administers her Mounjaro (tirzepatide) injection. She notes she lives in Belgium, signaling that access conditions differ from other countries, which is genuinely true and worth saying out loud. The cholesterol hashtag suggests she may also be framing tirzepatide partly through a cardiovascular or metabolic lens, not just weight loss. Self-injection tutorials have become one of the dominant GLP-1 content formats on TikTok, and most of them mix legitimately useful technique tips with individualized anecdote presented as general guidance. The concern here is not that she is injecting herself, that is standard practice for subcutaneous GLP-1 medications. The concern is that 252K viewers will absorb her personal protocol, her dosing schedule, her injection site preferences, and her side effect experience as if it applies to them.

What does the science actually show?

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for chronic weight management (Zepbound). The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15mg tirzepatide lost a mean of 20.9% body weight over 72 weeks compared to 3.1% on placebo. That is a clinically meaningful result. Injection technique does matter for subcutaneous medications. The standard recommendation is rotating sites between abdomen, thigh, and upper arm, using a new needle each time, and injecting at room temperature. Tirzepatide comes in a prefilled autoinjector pen, which simplifies the process significantly compared to older insulin-style syringes. None of this is controversial. What is less settled is whether informal social media tutorials, absent any clinical relationship, constitute safe patient education.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is the normalization of self-guided dose escalation. Tirzepatide is typically started at 2.5mg weekly and escalated in 2.5mg increments every four weeks, up to a maximum of 15mg. Creators frequently describe skipping escalation steps to accelerate weight loss, or staying at lower doses indefinitely to manage nausea, without mentioning that both approaches should involve a prescribing clinician. A secondary problem is the cholesterol framing. Tirzepatide does show favorable effects on lipid panels: the SURPASS-2 trial (Frías et al., 2021, New England Journal of Medicine) noted reductions in triglycerides and modest LDL improvements, but these are secondary outcomes, not a primary mechanism to lead with. Positioning tirzepatide as a cholesterol drug could draw in viewers who are not the appropriate clinical population for the medication, or who may have cardiovascular contraindications that require actual physician assessment.

What should you actually know?

If you are on tirzepatide, learning proper injection technique is genuinely useful, and your prescriber or pharmacist should be your first source. The autoinjector pen design means most errors are about site rotation and storage, not technique complexity. Mounjaro and Zepbound must be refrigerated at 2 to 8 degrees Celsius and can be kept at room temperature for up to 21 days. Do not inject into areas with active skin irritation, scarring, or bruising. Belgium's prescribing framework does differ from the Netherlands, the UK, and the US: in Belgium, tirzepatide for obesity is not reimbursed by the national health insurer as of 2024, meaning most patients pay out of pocket, which shapes who accesses it and how. That regulatory context the creator is nodding to is real and worth understanding. What a TikTok tutorial cannot provide is a clinical review of whether tirzepatide is appropriate for your specific metabolic profile, medication interactions, or contraindications.